Medication comparison
Semaglutide vs Tirzepatide for Weight Loss
Compare two leading incretin medicines across mechanism, approved brands, clinical evidence, dosing and common risks.
The short answer
These are distinct medicines with different receptor activity, brand indications and dose schedules. Comparing them requires the specific product and diagnosis—not an ingredient name alone.
Semaglutide vs Tirzepatide at a glance
The biggest difference is single versus dual incretin receptor activity. Milligram amounts across different active ingredients are not equivalent.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Receptors | GLP-1 | GIP and GLP-1 |
| U.S. brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Form | Injection; oral forms exist for specific brands | Injection |
| Frequency | Brand-dependent; often weekly | Weekly |
| Dose comparison | Not directly equivalent | Not directly equivalent |
May be best aligned with
Semaglutide
People suited to a GLP-1-only treatment pathway
- Extensive outcomes research
- Multiple formulations and labeled uses
- Longer post-market experience
May be best aligned with
Tirzepatide
People suited to combined GIP/GLP-1 treatment
- Dual receptor activity
- Strong comparative efficacy data
- Broad injectable dose ladder
How the medications work
These medications act on incretin pathways that influence glucose regulation, appetite and digestion. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Products with the same active ingredient can still have different FDA-approved indications, devices and dose schedules.
Weight-loss expectations
Clinical-trial averages are useful for understanding a population, not predicting an individual. Results depend on the product, dose reached, treatment duration, starting characteristics, adherence and the trial’s design. Some participants lose more than average, some less, and some stop because of side effects.
Side effects and safety
Common adverse effects include nausea, diarrhea, vomiting, constipation and abdominal discomfort. Product labels also describe less common but serious risks and contraindications. Both semaglutide and tirzepatide product labels include boxed warnings related to thyroid C-cell tumors observed in rodents; the relevance to humans is unknown. Review the current label and your personal and family history with a prescriber.
Cost, savings and insurance
Cash prices, formularies and manufacturer programs change. Coverage often follows the FDA-approved indication: a plan may cover a diabetes product for type 2 diabetes while excluding weight-management medication. Before enrolling in care, confirm the medication price, program fee, laboratory costs, prior-authorization support, renewal fee and cancellation terms.
How clinicians choose
A prescriber may review diagnosis, body-mass index where relevant, weight-related conditions, glucose and kidney measures, gastrointestinal history, pregnancy plans, current medications, prior treatment, eating-disorder history and your ability to follow up. The most effective option on paper is not always the most appropriate or accessible option for one person.
Consider these tradeoffs
- No dose-conversion formula
- GI effects are common with both
- Brand, indication and coverage matter
Frequently asked questions
Can I take semaglutide and tirzepatide together?
No. These medications are not intended to be used together. A licensed clinician should guide any switch and provide individualized timing instructions.
Which has fewer side effects, semaglutide or tirzepatide?
Both can cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation and abdominal discomfort. Individual tolerance varies, and gradual dose escalation may help. Review risks with your prescriber.
Does insurance cover semaglutide or tirzepatide?
Coverage depends on the plan, diagnosis, prior-authorization rules and formulary. Confirm benefits directly with the insurer and ask whether a specific indication is excluded.
Sources
- Ozempic prescribing information — U.S. Food and Drug Administration (2026-05)
- Wegovy prescribing information — U.S. Food and Drug Administration (2025-12)
- Mounjaro prescribing information — U.S. Food and Drug Administration (2026)
- Zepbound prescribing information — U.S. Food and Drug Administration (2026-02)
Related guidance
Medication comparisons
Wegovy vs Zepbound: Weight Loss, Dosing & Side Effects
A balanced comparison of FDA-approved weight-management medications semaglutide and tirzepatide.
13 min read
GLP-1 basics
7 Common GLP-1 Myths, Explained
What evidence and current labeling actually say about willpower, permanence, safety, muscle and lifestyle change.
11 min read
GLP-1 basics
How GLP-1 Medications Work
A plain-language guide to appetite, digestion, blood sugar and the differences among incretin medications.
9 min read